Sangamo Therapeutics

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Sangamo Therapeutics
Public
Traded asNASDAQSGMO
Russell 2000 Index component
IndustryBiotechnology
Founded1995
Headquarters
Key people
Sandy Macrae (CEO)
Edward Rebar (CTO)
Number of employees
182
Websitesangamo.com

Sangamo Therapeutics, Inc. (previously known as Sangamo Biosciences, Inc.) is an American biotechnology company based in Richmond, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.[1]

History[edit]

The company was founded in 1995 in Richmond, California.[2] It was originally known as Sangamo Biosciences, Inc. before changing names in 2017. In September 2018, it had 182 employees.[2] Sandy Macrae is the president.[3] In 2018, Edward Rebar became the senior vice president and chief technology officer of Sangamo.[4]

Research[edit]

Sangamo applies technology to treat haemophilia B and lysosomal storage diseases including mucopolysaccharidosis type I (Hurler Syndrome) and mucopolysaccharidosis type II (Hunter Syndrome). The FDA granted Sangamo fast track designation for SB-525, a gene therapy candidate for haemophilia A. In its partnership with Pfizer, Sangamo uses Bioverativ in hemoglobinopathies such as beta thalassemia and sickle cell disease.[1] It is also developing zinc finger gene editing technology.[5]

In February 2019, medical scientists, working with Sangamo Therapeutics, announced the first ever "in body" human gene editing therapy to permanently alter DNA - in a patient with Hunter Syndrome.[6] Clinical trials by Sangamo involving gene editing using Zinc Finger Nuclease (ZFN) are ongoing.[7]

References[edit]

  1. ^ a b McConaghie, Andrew (May 17, 2017). "Sangamo and new gene therapy partner Pfizer lifted by FDA fast track". Pharmaphorum. Retrieved October 1, 2018.
  2. ^ a b "Sangamo Therapeutics Inc. (SGMO) Moves Higher on Volume Spike for September 04". Equities. September 8, 2018. Retrieved October 1, 2018.
  3. ^ Ledford, Heidi (September 5, 2018). "First test of in-body gene editing shows promise". Nature. doi:10.1038/d41586-018-06195-6. ISSN 0028-0836.
  4. ^ "Sangamo Therapeutics appoints Edward Rebar as senior vice president". Post Online Media. Richmond, California. July 16, 2018. Retrieved October 1, 2018.
  5. ^ Renauer, Cory (September 6, 2018). "Sangamo's Zinc Fingers Fail Again. Time to Walk Away?". The Motley Fool. Retrieved October 1, 2018.
  6. ^ Marchione, Marilyn (February 7, 2019). "Tests suggest scientists achieved 1st 'in body' gene editing". AP News. Retrieved February 7, 2019.
  7. ^ Staff (February 2, 2019). "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II". ClinicalTrials.gov. U.S. National Library of Medicine. Retrieved February 7, 2019.

External links[edit]